Drug Type Small molecule drug |
Synonyms LivaloV, Livasartan, Pitavastatin/valsartan + [2] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (25 Feb 2015), |
Regulation- |
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | KR | 25 Feb 2015 | |
Heart Failure | KR | 25 Feb 2015 | |
Hypercholesterolemia | KR | 25 Feb 2015 | |
Myocardial Infarction | KR | 25 Feb 2015 |